1 year 14.74
Extreme 14.74
14.87
3 years 4.16
Extreme 4.16
16.63
5 years 2
Extreme 2
22.93
10 years 2
Extreme 2
47.25
Manager TitleAgeSince
Chief Executive Officer 60 2018-05-31
Director of Finance/CFO 49 2019-06-30
Chief Operating Officer 55 2024-08-04
Date Insider Type Main position Quantity % Market Cap. Importance
10/30/25 Tender

Founder

480,180 0.3234%
10/30/25
RA Capital Management LP
Issuer saleCompany 24,401,214 16.4326%
10/30/25 Free

Chief Technology Officer

1,357,397 0.9141%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 2.31B
-2.37%-5.03%+39.49%+62.39% 63.77B
-2.87%+0.49%+11.11%+69.18% 56.37B
+0.62%+2.11%+16.96%+102.56% 54.62B
-3.33%-5.54%+19.39%+35.69% 44.06B
-2.45%-2.59%+16.36%+98.45% 42.11B
-1.64%+2.32%+219.80%+789.69% 41B
-5.47%+24.76%+101.20%+87.34% 34.92B
+0.21%+1.05%+14.81%+46.96% 32.82B
-2.90%+17.12%-42.35%+337.07% 24.7B
Average -2.02%+6.84%+44.09%+181.04% 43.82B
Weighted average by Cap. -2.15%+4.83%+44.63%+163.55%
Logo 89bio, Inc.
89bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Pegozafermin is engineered to protect against proteolysis and reduce renal clearance and optimize its potency, enabling the potential use of a lower dosage/dose. Pegozafermin has been optimally constructed with two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the C-terminus end of the hormone.
Employees
93
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A
MarketScreener Ratings - 89bio, Inc.
  1. Stock Market
  2. Stocks
  3. ETNB Stock